SCHEDULE: Schonfeld Strategic Advisors Discloses 3.6% Stake in Skye Bioscience

Schonfeld Strategic Advisors LLC has filed an amended Schedule 13G, reporting beneficial ownership of 3.60% of Skye Bioscience, Inc.'s common stock.

Summary

• Schonfeld Strategic Advisors LLC reported beneficial ownership of 1,115,939 shares of Skye Bioscience, Inc. common stock.
• This represents 3.60% of the total outstanding common stock.
• The percentage is calculated based on 30,988,420 shares outstanding as of August 5, 2025, as reported in Skye Bioscience's Form 10-Q filed on August 7, 2025.
• Schonfeld Strategic Advisors LLC operates as an investment adviser.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of a passive institutional investment, which is generally a positive sign of investor interest, but it contains no new operational or financial information about the company itself.

Positives

• A significant institutional investor, Schonfeld Strategic Advisors LLC, holds a stake in Skye Bioscience, indicating potential confidence in the company.
• The filing explicitly states the shares were acquired and are held in the ordinary course of business, not for control purposes, suggesting a passive investment.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Skye Bioscience, Inc.'s future outlook.

Industry Context

This Schedule 13G filing indicates an institutional investment in Skye Bioscience, Inc., a common occurrence in the public markets where investment advisers like Schonfeld Strategic Advisors LLC take positions in companies as part of their portfolio management strategies. It reflects a passive investment below the 5% threshold that would trigger a Schedule 13D filing, which typically implies an intent to influence or control the issuer.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership by an institutional investor.
• It does not provide financial results or operational metrics for comparison to industry standards.
• The 3.60% stake is a typical passive investment size for an investment adviser.

Stakeholder Impact

• Shareholders: The disclosure of an institutional investor's stake may provide some level of confidence or validation for existing and potential shareholders.

Next Steps

• The filing does not specify any future actions or milestones for Skye Bioscience, Inc. or Schonfeld Strategic Advisors LLC beyond the ongoing beneficial ownership.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of a passive investment by Schonfeld Strategic Advisors LLC, holding 3.60% of Skye Bioscience, Inc. common stock. It indicates institutional interest but provides no new fundamental information about Skye Bioscience's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Investors should continue to monitor the company's core business developments and financial reports.

Keywords

Skye Bioscience, Schonfeld Strategic Advisors, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Investor